Virpax Pharmaceuticals, Inc., a Delaware-incorporated emerging growth company, has reported the issuance of 1,975,283 shares of common stock on July 11, 2024. This issuance was a result of investors exercising warrants previously issued by the company. The company received proceeds of approximately $2.67 million from this exercise. Following the issuance, the total number of outstanding shares of Virpax Pharmaceuticals' common stock increased to 4,813,181. The shares were issued under a registration statement on Form S-1, which was declared effective on May 14, 2024. The company's common stock is registered on The Nasdaq Capital Market under the trading symbol VRPX. The report was officially signed by Gerald Bruce, the Chief Executive Officer of Virpax Pharmaceuticals, on July 15, 2024.

Virpax Pharmaceuticals, Inc., a Delaware-incorporated emerging growth company, has reported the issuance of 1,975,283 shares of common stock on July 11, 2024. This issuance was a result of investors exercising warrants previously issued by the company. The company received proceeds of approximately $2.67 million from this exercise. Following the issuance, the total number of outstanding shares of Virpax Pharmaceuticals' common stock increased to 4,813,181. The shares were issued under a registration statement on Form S-1, which was declared effective on May 14, 2024. The company's common stock is registered on The Nasdaq Capital Market under the trading symbol VRPX. The report was officially signed by Gerald Bruce, the Chief Executive Officer of Virpax Pharmaceuticals, on July 15, 2024.